Abbott/Millennium Alliance Includes Focus On Obesity, Diabetes Markets
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories' $250 mil. joint development alliance with Millennium Pharmaceuticals for obesity and diabetes diagnostics and therapeutics will leverage Millennium's genomics expertise and is directed at products in the metabolic disease area.